End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
43.94 CNY | +2.16% | +1.48% | +9.74% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With an expected P/E ratio at 31.4 and 25.33 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.74% | 6.13B | C | ||
-31.79% | 15.12B | B- | ||
-21.99% | 12.26B | B | ||
-22.64% | 6.75B | B | ||
-10.91% | 6.03B | C+ | ||
+0.58% | 4.78B | D- | ||
+59.24% | 4.39B | - | C | |
-9.00% | 3.76B | B | ||
-12.53% | 3.43B | C- | ||
-7.34% | 3.07B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 603939 Stock
- Ratings Yifeng Pharmacy Chain Co., Ltd.